KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability: 2009-2025

Historic Non-Current Deferred Tax Liability for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $399.0 million.

  • Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability fell 25.84% to $399.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.0 million, marking a year-over-year decrease of 25.84%. This contributed to the annual value of $483.0 million for FY2024, which is 20.30% down from last year.
  • Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability amounted to $399.0 million in Q3 2025, which was down 9.32% from $440.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Non-Current Deferred Tax Liability high stood at $991.0 million for Q1 2021, and its period low was $399.0 million during Q3 2025.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Non-Current Deferred Tax Liability value was $538.0 million (recorded in 2024), while the average stood at $516.1 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first crashed by 44.73% in 2022, then increased by 10.58% in 2023.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Non-Current Deferred Tax Liability stood at $784.0 million in 2021, then crashed by 30.10% to $548.0 million in 2022, then increased by 10.58% to $606.0 million in 2023, then decreased by 20.30% to $483.0 million in 2024, then dropped by 25.84% to $399.0 million in 2025.
  • Its last three reported values are $399.0 million in Q3 2025, $440.0 million for Q2 2025, and $461.0 million during Q1 2025.